FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
Eli Lilly to sell Zepbound directly to consumers without ... - ABC News
Aug 27, 2024 · Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.
Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 · The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that...
FDA Approves Lilly's Zepbound™ (tirzepatide ... - Eli Lilly and Company
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea
Dec 20, 2024 · The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
FDA Approves First Medication for Obstructive Sleep Apnea
Zepbound received Fast Track, Priority Review and Breakthrough Therapy designations for this indication. The FDA granted the approval to Eli Lilly and Co. Boilerplate
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea
2 days ago · According to a recent news release, Eli Lilly's clinical trials for Zepbound showed promising results. After one year, patients experienced an average of 25 fewer breathing interruptions per hour.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound
Dec 23, 2024 · Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday. Trials of...
Medicare can cover Zepbound for sleep apnea, creating a …
3 days ago · Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company. The U.S ...